Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...
The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback